Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Lilly Drug Patent Portfolio

Lilly owns 20 orange book drugs protected by 55 US patents with Humulin 70/30 having the least patent protection, holding only 1 patent. And Evista with maximum patent protection, holding 13 patents. Given below is the list of Lilly's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7517334 Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose 25 Mar, 2025 Expired
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024 Expired
US7772209 Antifolate combination therapies 24 May, 2022 Expired
US7772209 Antifolate combination therapies 24 Nov, 2021 Expired
US6821975 Beta-carboline drug products 19 May, 2021 Expired
US6821975 Beta-carboline drug products 19 Nov, 2020 Expired
US6943166 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction 26 Oct, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Oct, 2020 Expired
US6943166 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction 26 Apr, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020 Expired
US6596756 Treatment of fibromyalgia 10 Mar, 2020 Expired
US6596756 Treatment of fibromyalgia 10 Sep, 2019 Expired
US6977077 Method of increasing bone toughness and stiffness and reducing fractures 19 Aug, 2019 Expired
US7163684 Method of increasing bone toughness and stiffness and reducing fractures 19 Aug, 2019 Expired
US7351414 Method of reducing the risk of bone fracture 19 Aug, 2019 Expired
US6770623 Stabilized teriparatide solutions 08 Dec, 2018 Expired
US7144861 Stabilized teriparatide solutions 08 Dec, 2018 Expired
US7550434 Stabilized teriparatide solutions 08 Dec, 2018 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 May, 2018 Expired
US5910319 Fluoxetine enteric pellets and methods for their preparation and use 29 Nov, 2017 Expired
US5985322 Method for the treatment of CNS disorders 29 Nov, 2017 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017 Expired
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017 Expired
US5910319 Fluoxetine enteric pellets and methods for their preparation and use 29 May, 2017 Expired
US5985322 Method for the treatment of CNS disorders 29 May, 2017 Expired
USRE39030 Fluoxetine enteric pellets and methods for their preparation and use 29 May, 2017 Expired
US5658590 Treatment of attention-deficit/hyperactivity disorder 26 May, 2017 Expired
US5945416 Method for treating pain 24 Mar, 2017 Expired
US6458811 Benzothiophenes formulations containing same and methods 10 Mar, 2017 Expired
US6797719 Benzothiophenes, formulations containing same, and methods 10 Mar, 2017 Expired
US6894064 Benzothiophenes, formulations containing same, and methods 10 Mar, 2017 Expired
US8030330 Benzothiophenes, formulations containing same, and methods 10 Mar, 2017 Expired
US5344932 N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives 24 Jan, 2017 Expired
US5658590 Treatment of attention-deficit/hyperactivity disorder 26 Nov, 2016 Expired
US5344932 N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives 24 Jul, 2016 Expired
US6140329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence 11 Jul, 2016 Expired
US5508276 Duloxetine enteric pellets 18 Jan, 2015 Expired
US5508276 Duloxetine enteric pellets 18 Jul, 2014 Expired
US5474978 Insulin analog formulations 16 Jun, 2014 Expired
US5461031 Monomeric insulin analog formulations 16 Jun, 2014 Expired
US5747642 Monomeric insulin analog formulations 16 Jun, 2014 Expired
US5478847 Methods of use for inhibiting bone loss and lowering serum cholesterol 02 Mar, 2014 Expired
US5811120 Solid orally administerable raloxifene hydrochloride pharmaceutical formulation 02 Mar, 2014 Expired
US5972383 Solid orally administerable raloxifene hydrochloride pharmaceutical formulation 02 Mar, 2014 Expired
USRE39050 Methods of use for inhibiting bone loss and lowering serum cholesterol 02 Mar, 2014 Expired
US5023269 3-aryloxy-3-substituted propanamines 11 Dec, 2013 Expired
US5023269 3-aryloxy-3-substituted propanamines 11 Jun, 2013 Expired
US5464826 Method of treating tumors in mammals with 2',2'-difluoronucleosides 07 May, 2013 Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013 Expired
US5464826 Method of treating tumors in mammals with 2',2'-difluoronucleosides 07 Nov, 2012 Expired
US5393763 Methods for inhibiting bone loss 28 Jul, 2012 Expired
US5457117 Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride 28 Jul, 2012 Expired
US6906086 Methods for inhibiting bone loss 28 Jul, 2012 Expired
USRE38968 Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride 28 Jul, 2012 Expired
USRE39049 Methods for inhibiting bone loss 28 Jul, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Lilly.

Activity Date Patent Number
Patent litigations
Expire Patent
Critical
12 Sep, 2022 US7772209 (Litigated)
Maintenance Fee Reminder Mailed
Critical
28 Mar, 2022 US7772209 (Litigated)
Expire Patent
Critical
26 Jul, 2021 US7550434
Maintenance Fee Reminder Mailed
Critical
08 Feb, 2021 US7550434
Payment of Maintenance Fee, 12th Year, Large Entity 15 Sep, 2020 US7517334
Expire Patent
Critical
04 May, 2020 US7351414
Maintenance Fee Reminder Mailed
Critical
18 Nov, 2019 US7351414
Expire Patent
Critical
11 Nov, 2019 US8030330
Review Certificate Mailed 26 Sep, 2019 US7772209 (Litigated)
Review Certificate 06 Sep, 2019 US7772209 (Litigated)
Review Certificate Mailed 27 Jun, 2019 US6821975 (Litigated)
Review Certificate Mailed 26 Jun, 2019 US7182958 (Litigated)
Review Certificate 12 Jun, 2019 US6821975 (Litigated)
Review Certificate 12 Jun, 2019 US7182958 (Litigated)
Maintenance Fee Reminder Mailed
Critical
27 May, 2019 US8030330


Lilly's Drug Patent Litigations

Lilly's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 14, 2013, against patent number US7772209. The petitioner Accord Healthcare, Inc., USA, challenged the validity of this patent, with Eli Lilly and Company as the respondent. Click below to track the latest information on how companies are challenging Lilly's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6943166 June, 2018 Institution Denied
(07 Dec, 2018)
ICOS Corporation et al. Aquestive Therapeutics, Inc.
US6943166 July, 2017 Terminated-Settled
(27 Oct, 2017)
ICOS Corporation Dr. Reddy's Laboratories, Inc.
US7772209 November, 2015 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Neptune Generics, LLC et al.
US7772209 December, 2015 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Sandoz Inc.
US7772209 June, 2016 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Wockhardt Bio AG et al.
US7772209 July, 2016 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Apotex Inc. et al.
US7772209 July, 2016 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Teva Pharmaceuticals USA, Inc. et al.
US7772209 July, 2016 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Wockhardt Bio AG et al.
US7772209 July, 2016 Final Written Decision
(05 Oct, 2017)
Eli Lilly and Company Apotex Inc. et al.
US6943166 July, 2017 Terminated-Settled
(03 Oct, 2017)
ICOS Corporation Argentum Pharmaceuticals LLC
US6943166 November, 2016 Terminated-Settled
(16 Aug, 2017)
ICOS Corporation Mylan Pharmaceuticals Inc.
US6943166 December, 2016 Institution Denied
(03 Jul, 2017)
ICOS Corporation et al. MonoSol Rx, LLC
US6943166 February, 2016 Institution Denied
(01 Sep, 2016)
ICOS Corporation et al. IntelGenx Corp.
US6821975 January, 2015 Final Written Decision
(03 Aug, 2016)
ICOS Corporation et al. Actelion Pharmaceuticals Ltd
US7182958 January, 2015 Final Written Decision
(03 Aug, 2016)
ICOS Corporation et al. Actelion Pharmaceuticals Ltd
US7772209 June, 2013 Institution Denied
(01 Oct, 2013)
Eli Lilly and Company Accord Healthcare, Inc., USA


Lilly Drug Patents' Oppositions Filed in EPO

Lilly drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 17, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP01948214A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP01948214A Oct, 2012 Actavis Deutschland GmbH & Co. KG Opposition rejected
EP01948214A Jan, 2008 Teva Pharmaceutical Industries Ltd. Opposition rejected


Lilly's Family Patents

Lilly drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 23.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Lilly:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Sep 1, 2026)
PHASE2
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LY3526318 in Healthy Male Japanese Participants Eli Lilly and Company NA WITHDRAWN
(Sep 1, 2026)
PHASE1
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of LY4257496 in Participants With Cancer (OMNIRAY) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of Brenipatide in Participants With Alcohol Use Disorder Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Brenipatide in Participants With Opioid Use Disorder Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study of LY4355756 in Healthy Participants Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight Eli Lilly and Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Eli Lilly and Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) Eli Lilly and Company NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Abemaciclib (LY2835219) in Healthy Participants Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 Eli Lilly and Company NA RECRUITING
(Aug 1, 2026)
PHASE1
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer Eli Lilly and Company NA RECRUITING
(Aug 1, 2026)
PHASE2
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Eli Lilly and Company NA COMPLETED
(Aug 1, 2026)
PHASE3
A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Aug 1, 2026)
PHASE1
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE3
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE1
A Study of Baricitinib (LY3009104) in Children With COVID-19 Eli Lilly and Company NA TERMINATED
(Jul 1, 2026)
PHASE3
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Eli Lilly and Company NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Eli Lilly and Company NA COMPLETED
(Jul 1, 2026)
PHASE2
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study of LY4515100 in Healthy Participants Eli Lilly and Company NA RECRUITING
(Jul 1, 2026)
PHASE1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study of LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE3
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE2
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE1
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE3
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Eli Lilly and Company NA COMPLETED
(Jun 1, 2026)
PHASE3
A Study of LY4175408 in Participants With Advanced Cancer Eli Lilly and Company NA RECRUITING
(Jun 1, 2026)
PHASE1
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Eli Lilly and Company NA COMPLETED
(May 1, 2026)
PHASE2
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Eli Lilly and Company NA COMPLETED
(May 1, 2026)
PHASE3
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Eli Lilly and Company NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Eli Lilly and Company NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus Eli Lilly and Company NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
A Study of Olomorasib (LY3537982) in Healthy Participants Eli Lilly and Company NA COMPLETED
(May 1, 2026)
PHASE1
A Multiple Dose Study of LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 15, 2026)
PHASE1
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 15, 2026)
PHASE1
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Eli Lilly and Company NA COMPLETED
(Mar 1, 2026)
PHASE2, PHASE3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Eli Lilly and Company NA COMPLETED
(Mar 1, 2026)
PHASE3
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company NA COMPLETED
(Mar 1, 2026)
PHASE3
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Eli Lilly and Company NA RECRUITING
(Sep, 2024)
PHASE2
A Study of LY3841136 in Overweight and Obese Participants Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE1
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Eli Lilly and Company NA COMPLETED
(Aug, 2024)
PHASE4
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Eli Lilly and Company Regeneron Pharmaceuticals RECRUITING
(Aug, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Eli Lilly and Company NA COMPLETED
(Jul, 2024)
PHASE3
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul, 2024)
PHASE3
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Eli Lilly and Company NA COMPLETED
(Apr, 2024)
PHASE2
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes Eli Lilly and Company NA COMPLETED
(Jun, 2022)
PHASE1
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Eli Lilly and Company NA COMPLETED
(Jan, 2022)
PHASE3


Lilly Drug List

Given below is the complete list of Lilly's drugs and the patents protecting them.


1. Alimta

Alimta is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7772209
(Pediatric)
Antifolate combination therapies 24 May, 2022
(4 years ago)
Expired
US7772209 Antifolate combination therapies 24 Nov, 2021
(4 years ago)
Expired
US5344932
(Pediatric)
N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives 24 Jan, 2017
(9 years ago)
Expired
US5344932 N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives 24 Jul, 2016
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alimta's drug page


2. Cialis

Cialis is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6821975
(Pediatric)
Beta-carboline drug products 19 May, 2021
(5 years ago)
Expired
US6821975 Beta-carboline drug products 19 Nov, 2020
(5 years ago)
Expired
US6943166
(Pediatric)
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction 26 Oct, 2020
(5 years ago)
Expired
US7182958
(Pediatric)
β-carboline pharmaceutical compositions 26 Oct, 2020
(5 years ago)
Expired
US6943166 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction 26 Apr, 2020
(6 years ago)
Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020
(6 years ago)
Expired
US5859006
(Pediatric)
Tetracyclic derivatives; process of preparation and use 21 May, 2018
(8 years ago)
Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017
(8 years ago)
Expired
US6140329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence 11 Jul, 2016
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cialis's drug page


3. Cymbalta

Cymbalta is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6596756
(Pediatric)
Treatment of fibromyalgia 10 Mar, 2020
(6 years ago)
Expired
US6596756 Treatment of fibromyalgia 10 Sep, 2019
(7 years ago)
Expired
US5508276
(Pediatric)
Duloxetine enteric pellets 18 Jan, 2015
(11 years ago)
Expired
US5508276 Duloxetine enteric pellets 18 Jul, 2014
(12 years ago)
Expired
US5023269
(Pediatric)
3-aryloxy-3-substituted propanamines 11 Dec, 2013
(12 years ago)
Expired
US5023269 3-aryloxy-3-substituted propanamines 11 Jun, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cymbalta's drug page


4. Evista

Evista is protected by 13 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6458811 Benzothiophenes formulations containing same and methods 10 Mar, 2017
(9 years ago)
Expired
US6797719 Benzothiophenes, formulations containing same, and methods 10 Mar, 2017
(9 years ago)
Expired
US6894064 Benzothiophenes, formulations containing same, and methods 10 Mar, 2017
(9 years ago)
Expired
US8030330 Benzothiophenes, formulations containing same, and methods 10 Mar, 2017
(9 years ago)
Expired
US5478847 Methods of use for inhibiting bone loss and lowering serum cholesterol 02 Mar, 2014
(12 years ago)
Expired
US5811120 Solid orally administerable raloxifene hydrochloride pharmaceutical formulation 02 Mar, 2014
(12 years ago)
Expired
US5972383 Solid orally administerable raloxifene hydrochloride pharmaceutical formulation 02 Mar, 2014
(12 years ago)
Expired
USRE39050 Methods of use for inhibiting bone loss and lowering serum cholesterol 02 Mar, 2014
(12 years ago)
Expired
US5393763 Methods for inhibiting bone loss 28 Jul, 2012
(14 years ago)
Expired
US5457117 Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride 28 Jul, 2012
(14 years ago)
Expired
US6906086 Methods for inhibiting bone loss 28 Jul, 2012
(14 years ago)
Expired
USRE38968 Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride 28 Jul, 2012
(14 years ago)
Expired
USRE39049 Methods for inhibiting bone loss 28 Jul, 2012
(14 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evista's drug page


5. Forteo

Forteo is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7517334 Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose 25 Mar, 2025
(1 year, 6 months ago)
Expired
US6977077 Method of increasing bone toughness and stiffness and reducing fractures 19 Aug, 2019
(7 years ago)
Expired
US7163684 Method of increasing bone toughness and stiffness and reducing fractures 19 Aug, 2019
(7 years ago)
Expired
US7351414 Method of reducing the risk of bone fracture 19 Aug, 2019
(7 years ago)
Expired
US6770623 Stabilized teriparatide solutions 08 Dec, 2018
(7 years ago)
Expired
US7144861 Stabilized teriparatide solutions 08 Dec, 2018
(7 years ago)
Expired
US7550434 Stabilized teriparatide solutions 08 Dec, 2018
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Forteo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Gemzar

Gemzar is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5464826
(Pediatric)
Method of treating tumors in mammals with 2',2'-difluoronucleosides 07 May, 2013
(13 years ago)
Expired
US5464826 Method of treating tumors in mammals with 2',2'-difluoronucleosides 07 Nov, 2012
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gemzar's drug page


7. Humalog

Humalog is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog's drug page


8. Humalog Kwikpen

Humalog Kwikpen is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Kwikpen's drug page


9. Humalog Mix 50/50

Humalog Mix 50/50 is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5461031 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5747642 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 50/50's drug page


10. Humalog Mix 50/50 Kwikpen

Humalog Mix 50/50 Kwikpen is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired
US5461031 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5747642 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 50/50 Kwikpen's drug page


11. Humalog Mix 75/25

Humalog Mix 75/25 is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5461031 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5747642 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 75/25's drug page


12. Humalog Mix 75/25 Kwikpen

Humalog Mix 75/25 Kwikpen is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired
US5461031 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5747642 Monomeric insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Mix 75/25 Kwikpen's drug page


13. Humalog Pen

Humalog Pen is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5474978 Insulin analog formulations 16 Jun, 2014
(12 years ago)
Expired
US5514646 Insulin analogs modified at position 29 of the B chain 07 May, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Pen's drug page


14. Humulin 70/30

Humulin 70/30 is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin 70/30's drug page


15. Humulin 70/30 Pen

Humulin 70/30 Pen is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin 70/30 Pen's drug page


16. Humulin N

Humulin N is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin N's drug page


17. Humulin R

Humulin R is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humulin R's drug page


18. Prozac Weekly

Prozac Weekly is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5910319
(Pediatric)
Fluoxetine enteric pellets and methods for their preparation and use 29 Nov, 2017
(8 years ago)
Expired
US5985322
(Pediatric)
Method for the treatment of CNS disorders 29 Nov, 2017
(8 years ago)
Expired
US5910319 Fluoxetine enteric pellets and methods for their preparation and use 29 May, 2017
(9 years ago)
Expired
US5985322 Method for the treatment of CNS disorders 29 May, 2017
(9 years ago)
Expired
USRE39030 Fluoxetine enteric pellets and methods for their preparation and use 29 May, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prozac Weekly's drug page


19. Strattera

Strattera is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5658590
(Pediatric)
Treatment of attention-deficit/hyperactivity disorder 26 May, 2017
(9 years ago)
Expired
US5658590 Treatment of attention-deficit/hyperactivity disorder 26 Nov, 2016
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Strattera's drug page


20. Symbyax

Symbyax is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017
(8 years ago)
Expired
US5945416 Method for treating pain 24 Mar, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symbyax's drug page


Lilly News

Novo Nordisk A/S shares (DK0062498333): Can its leading position in obesity medications sustain...

19 Apr, 2026

Amgen Inc. shares (US0311621009): Can the momentum of its obesity medication maintain long-term growth?

14 Apr, 2026

Rothschild & Co Redburn Increases Eli Lilly's Price Target to $880 - Indianapolis Today

11 Apr, 2026

Exploring Eli Lilly's $7.8 Billion Purchase of Centessa Pharmaceuticals: The Orexin Boom

01 Apr, 2026

See More